Cryo-Cell International Inc. (CCEL)
Stock Price:
$8.85 USD
0.00 (0.00%)
Updated Aug 7, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
66.78M |
| Revenue (ttm) |
31.69M |
| Net Income (ttm) |
3.60M |
| Shares Out |
7.55M |
| EPS (ttm) |
0.43 |
| PE Ratio |
20.58 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$8.85 |
| Previous Close |
$8.85 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
8.89 |
| Day's Range |
8.40 - 8.90 |
| Day's Volume |
7,752 |
| 52-Week Range |
4.52 - 9.00 |
More Stats
| Market Cap |
66.78M |
| Enterprise Value |
65.34M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
7.55M |
| Float |
2.42M |
| EPS (basic) |
0.46 |
| EPS (diluted) |
0.43 |
| FCF / Share |
0.94 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
4.86% |
| FCF Yield |
10.65% |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.08 |
| PE Ratio |
20.58 |
| Forward PE |
n/a |
| P/FCF Ratio |
9.39 |
| PS Ratio |
2.11 |
| PB Ratio |
n/a |
| Revenue |
31.69M |
| Operating Income |
6.62M |
| Net Income |
3.60M |
| Free Cash Flow |
7.11M |
| Net Cash |
1.44M |
| Net Cash / Share |
0.19 |
| Gross Margin |
61.38% |
| Operating Margin |
20.89% |
| Profit Margin |
11.40% |
| FCF Margin |
22.44% |
| ROA |
9.65% |
| ROE |
n/a |
| ROIC |
25.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
5.28
Current: $8.85
High
5.28
Target: 5.28
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 31.82 | 29.22 | 25.38 | 23.13 | 21.09 | 20.13 | 18.99 | 17.97 | 17.92 | 17.76 |
| Revenue Growth | 8.89% | 15.1% | 9.76% | 9.66% | 4.79% | 5.96% | 5.7% | 0.29% | 0.88% | - |
| Gross Profit | 21.78 | 20.68 | 18.66 | 17.35 | 15.46 | 14.49 | 13.67 | 13.08 | 13.52 | 13.26 |
| Operating Income | 4.32 | 4.77 | 5.01 | 0.43 | 2.93 | 1.98 | 1.70 | -1.71 | -0.28 | 3.35 |
| Net Income | 2.29 | -0.85 | 2.32 | -1.32 | 8.11 | 0.55 | 0.03 | -6.31 | -2.10 | 3.46 |
| Shares Outstanding | 7.79 | 7.46 | 7.06 | 8.11 | 9.54 | 10.18 | 10.86 | 11.31 | 11.76 | 11.75 |
| Earnings Per Share | 0.27 | -0.11 | 0.30 | -0.16 | 0.83 | 0.05 | - | -0.56 | -0.18 | 0.29 |
| EPS Growth | - | - | - | - | 1560% | - | - | - | - | - |
| Operating Cash Flow | 6.32 | 5.33 | 5.72 | 4.99 | 4.85 | 1.55 | 0.82 | 0.36 | 0.82 | 2.34 |
| Capital Expenditures | -0.66 | -0.65 | -0.10 | -0.34 | -0.11 | -0.12 | -0.35 | -0.13 | -0.51 | -0.40 |
| Free Cash Flow | 5.66 | 4.69 | 5.62 | 4.64 | 4.74 | 1.43 | 0.47 | 0.23 | 0.31 | 1.94 |
| Cash & Equivalents | 7.45 | 6.92 | 6.72 | 4.12 | 4.97 | 3.59 | 5.48 | 5.82 | 10.01 | 9.70 |
| Total Debt | 8.96 | 12.94 | 7.30 | 9.82 | 1.18 | - | - | - | - | - |
| Net Cash / Debt | -1.51 | -6.03 | -0.58 | -5.70 | 3.79 | 3.59 | 5.48 | 5.82 | 10.01 | 9.70 |
| Assets | 42.89 | 42.39 | 23.91 | 19.54 | 19.50 | 10.21 | 11.50 | 12.33 | 19.47 | 18.09 |
| Liabilities | 49.84 | 51.30 | 36.41 | 34.95 | 24.46 | 20.94 | 20.77 | 21.33 | 21.93 | 19.09 |
| Book Value | -6.95 | -8.91 | -12.50 | -15.41 | -4.96 | -10.73 | -9.27 | -9.00 | -2.46 | -1.00 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cryo-Cell International Inc. |
| Country |
United States |
| Employees |
87 |
| CEO |
Mark L. Portnoy / David I. Portnoy |
Stock Information
| Ticker Symbol |
CCEL |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Medical Care Facilities |
| Unique Identifier |
OTCMKTS: CCEL |
| IPO Date |
January 21, 1997 |
Description
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue specimens worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was founded in 1989 and is headquartered in Oldsmar, Florida.